Eighty percent of these cases harbor concurrent CDKN2A/B and IKZF1 deletions and have poor outcomes with <40% overall survival, similar to other bcr-abl-like ALL [70]. This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.